UBC finalizes first global access agreement for a new therapy

Posted on May 27, 2008. Filed under: UBC-UAEM news |

Earlier this month, UBC announced that the license agreement for Dr. Kishor Wasan’s new oral formulation of anti-fungal and anti-Leishmania drug Amphotericin B has been finalized. The agreement with iCo Therapeutics Inc. includes mechanisms to promote the availability of the drug in low- and middle-income countries, and is the first global access agreement on a new drug to be executed under UBC’s new global access principles. We at UAEM think that UBC deserves enthusiastic congratulations for its efforts on this project!

Read more in UBC’s press release.

Advertisement

Make a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Connecting to %s

  • Our drugs. Our labs. Our responsibility.

    UAEM logo

    UAEM is a group of students dedicated to enhancing the impact of our universities' biomedical research on global health.

    We advocate for new medicines to be made more accessible in poor countries, and for more research on the diseases of the poor.

    Learn more about the issues here.

Liked it here?
Why not try sites on the blogroll...

Follow

Get every new post delivered to your Inbox.